Tolerability assessment of a lectin fraction from Tepary bean seeds (Phaseolus acutifolius) orally administered to rats  by Ferriz-Martínez, Roberto et al.
T
s
R
A
U
A
J
H
T
a
b
c
C
a
A
R
R
A
A
K
A
L
P
T
M
2
(Toxicology Reports 2 (2015) 63–69
Contents lists available at ScienceDirect
Toxicology  Reports
journa l h om epa ge: www.elsev ier .com/ locate / toxrep
olerability  assessment  of  a  lectin  fraction  from  Tepary  bean
eeds  (Phaseolus  acutifolius) orally  administered  to  rats
oberto  Ferriz-Martíneza,  Karina  García-Garcíaa, Iovanna  Torres-Arteagaa,
driana  Jheny  Rodriguez-Mendezb,  María  de  Jesús  Guerrero-Carrilloa,
lisses  Moreno-Celisa, Marco  Vinicio  Ángeles-Zaragozaa,
lejandro  Blanco-Labrac,  Marco  Alonso  Gallegos-Coronab,
uan Pablo  Robles-Álvareza, Elizabeth  Mendiola-Olayac,
éctor  Mario  Andrade-Montemayora, Olga  Patricia  Garciaa,
eresa  Garcia-Gascaa,∗
Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, P.O. Box 184, Querétaro 76010, Qro., C.P. 76230, Mexico
Facultad de Medicina, Universidad Autónoma de Querétaro, P.O. Box 184, Querétaro 76010, Qro., Mexico
Departamento de Biotecnología y Bioquímica, Centro de Investigación y Estudios Avanzados del IPN, P.O. Box 629, Irapuato, Gto.,
.P.  36821, Mexico
 r  t  i c  l  e  i  n  f  o
rticle history:
eceived 1 June 2014
eceived in revised form 19 October 2014
ccepted 20 October 2014
vailable online 8 November 2014
eywords:
ntinutritional factors
ectins toxicity
haseolus acutifolius
epary bean
a  b  s  t  r  a  c  t
Our previous  studies  have  shown  that  a lectin  rich  fraction  (TBLF)  extracted  from  Tepary
bean  seeds  differentially  inhibits  cancer  cells  proliferation  in  vitro.  Before  testing  the in vivo
anticancer  effect,  the acute  and  subchronic  toxicological  assays  in rats  were  conducted,
where  an  oral  dose  of  50 mg/body  weight  kg was  determined  as the  NOAEL.  This  study
evaluated  the resistance  to  digestion  and  complete  blood  count  (CBC)  after  24  h  of the
orally  administered  50 mg/kg  TBLF.  The  digestion  resistance  test  showed  lectins  activity
retention  after  72  h and  the  CBC  study  showed  a high  level  of  eosinophils,  suggesting  an
allergic-like  response.  Tolerability  was  assayed  after  6 weeks  of  treatment  by  dosing  with
an intragastric  cannula  every  third  day  per  week.  It was  observed  a  transient  reduction  in
food intake  and  body  weight  in  the  ﬁrst  weeks,  resulting  in  body  weight  gain  reduction
of  10%  respect  to the  control  group  at the  end of the  study.  Additionally,  organs  weight,
histopathological  analysis  and  blood  markers  for  nutritional  status  and  for  liver, pancreas
and  renal  function  were  not  affected.  Our  results  suggest  that 50 mg/kg  TBLF  administered
by  oral  route,  exhibit  no  toxicity  in  rats  and  it was  well  tolerated.  Further  studies  will focus
on long-term  studies.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  underthe  CC  BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).∗ Corresponding author at: Facultad de Ciencias Naturales, Universidad Autóno
exico. Tel.: +52 4421921200 ext 5308; fax: +52 442 2342958.
E-mail address: tggasca@uaq.edu.mx (T. Garcia-Gasca).
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1. Introduction
Lectins include a group of proteins from non-immune
origin that share the property of binding speciﬁcally and
reversibly to carbohydrates [1]. Many plant lectins have
attracted the attention due to their effects on proliferation
and differentiation of animal cells, including lymphocytes
and cancer cells. The in vitro and the in vivo antitumor
effects of plant lectins are apparently associated with their
ability to modulate growth, differentiation, proliferation
and apoptosis [2–4].
Toxicity of lectins must be considered before used
as medical tools, mainly because they are considered
antinutritional factors. It has been shown that binding
lectins to intestinal epithelium can interfere with nutri-
ent absorption, reduction of nitrogen retention, increased
urine nitrogen excretion and reduction of insulin produc-
tion in rats [5–8]. Antinutritional and negative effects on
digestion and absorption have been described for lectins
from different sources [9–12]. Studies with common bean
(Phaseolus vulgaris L.) lectins show that they can inter-
fere with bowel function, causing changes in systemic
metabolism and affecting the growth in rats, decrease in
glucose, lipids, vitamin B12 and nitrogen uptake [13,14].
Adverse effects in organs are produced by some diet
lectins, which included Phaseolus vulgaris. Rats fed with
navy beans showed morphological changes that include
increased weight of kidney and heart, pancreatic acinar
atrophy, fatty liver and multiple histological lesions as thy-
mus  atrophy respect to control healthy rats. Death by lectin
administration can be produced by different mechanisms
including the reduced availability of nitrogen in the body,
the induction of bacterial overgrowth in the small intestine,
the effects on blood cells or acting as ribosome inactivating
proteins [15,16].
Some studies showed that intraperitoneal administra-
tion of Tepary bean (Phaseolus acutifolius)  crude extract
presented toxic effects as weight loss, negative efﬁciency
on protein ratio, negative net protein utilization, poor
digestion of proteins and death of rats and mice after
10 days treatment, however, after autoclaving the crude
extract, the toxic effects were lost [17]. Studies on the tox-
icity of semipure lectins from Tepary bean intraperitoneally
administrated in CD-1 mice, found a lethal dose (LD50) of
1100 and 1120 mg/kg body weight for males and females,
respectively [18].
A semipure lectin fraction from Tepary bean seeds
(TBLF) obtained by a molecular weight exclusion chro-
matography protocol exhibits in vitro antiproliferative
differential effect on cancer and normal cells [19]. Before
testing the in vivo anticancer effect, we studied the
acute toxicity of TBLF using intragastric doses from 5
to 2000 mg/body weight kg suggesting a secure dose of
50 mg/kg. The intragastric 50 mg/kg TBLF dose was assayed
for subchronic toxicity (daily dosing for 28 days) where no
toxic or adverse effects were observed, therefore 50 mg/kg
TBLF was determined as the NOAEL [20]. Here we  present
a short-term assay in order to know the digestion resis-
tance of lectins and the effect on complete blood count
(CBC) after 24 h of 50 mg/kg TBLF single-dose administra-
tion. The anti-nutritional effects and toxic parameters of ay Reports 2 (2015) 63–69
6-week schedule study (intragastric administration every
third day) were studied; where food intake, body weight,
biochemical blood markers and histopathological analysis
were included.
2. Materials and methods
2.1. Experimental animals
Sprague Dawley (SD) rats were purchased from Insti-
tute of Neurobiology, Universidad Nacional Autonoma de
Mexico (INB-UNAM) and placed in individual cages with
ad libitum water and rodent chow food (Rodent Laboratory
Chow 5001, Saint Louis, MO,  USA). The animals remained
1 week for acclimatization where the circadian cycle was
adjusted to 12 h light/12 h darkness, at 22 ◦C and a relative
humidity of 30%. The animals were sacriﬁced by decap-
itation at the end of the experiments. The experimental
protocol was  based on the Mexican ofﬁcial standard [21]
and approved by the INB-UNAM ethics committee.
2.2. Tepary bean lectin fraction (TBLF)
We  have performed a standardized method for TBLF
obtaining [19]. Some modiﬁcations were done in order
to improve the lectin enrichment. Brieﬂy, Tepary bean
seeds were grinded (A-10 Analytical Tekmar mill) and
degreased with chloroform-methanol 2:1 in a 4:1 w/v pro-
portion, stirring for 15 min and then vacuum ﬁlter; this
process was repeated 2 more times and ﬂour was dried
at room temperature in a fume hood. In order to obtain
the crude extract, 100 g of degreased ﬂour were dissolved
in 500 mL  of 50 mM Tris–HCl pH 8 with stirring for 12 h at
4 ◦C and centrifuging at 39,200 × g for 60 min  (Bekman JA-
20 centrifuge). A sequential precipitation was  done using
40% ammonium sulphate saturation with slow stirring for
30 min, equilibrating for 30 min  at 4 ◦C and centrifuging at
39,200 × g for 45 min. The supernatant was precipitated
with 60% ammonium sulfate saturation and treated as
previously described, but in this case the precipitate was
recovered and the supernatant was discarded. The frac-
tion was resuspended in a minimum volume of deionizer
water, dialyzed through a 3-kDa pore size membrane and
centrifuged, loading 4 mL  aliquots on a Sephadex G-75
gel ﬁltration 167 cm × 1.7 cm column (Pharmacia Biotech,
Uppsala, Switzerland). The column was equilibrated with
0.01 M ammonium bicarbonate buffer pH 7.8. The experi-
ment was performed at 4 ◦C collecting 0.3 mL/min fractions
with the same buffer. Protein was  monitored at 280 nm
in a Beckman DU-65 spectrophotometer. Agglutination
activity [22] was  determined by microscopic counting
using glutaraldehyde-ﬁxed type A+ human erythrocytes
[23]. Speciﬁc activity was determined using protein con-
centration [24]. Electrophoretic proﬁle was  obtained by
10% polyacrylamide SDS-PAGE [25]. Glycoproteins were
conﬁrmed by periodic acid-Schiff staining (PASS) [26].
Additionally, lectins were observed by western blot using
an anti-phytohemagglutinin antibody from Phaseolus vul-
garis (Vector Laboratories Inc. Burlingame, CA, USA. cat.
oxicology Reports 2 (2015) 63–69 65
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Fig. 1. TBLF electrophoretic proﬁle and lectins identiﬁcation. TBLF was
obtained by molecular weight exclusion chromatography. Monodimen-
sional SDS-PAGE was  performed. (1) Molecular weight markers, (2) TBLF,R. Ferriz-Martínez et al. / T
o. AS-2300). The fraction was dialyzed against deionized
ater, lyophilized and stored at −20 ◦C until use.
.3. Digestion-resistance assay and complete blood count
CBC) determination after a single dose of TBLF
Five-week old male SD rats were divided into 2 groups
n = 8 per group). After fasting for 24 h, the treated group
eceived a single dose of the lyophilized 50 mg/kg TBLF
issolved in standard saline solution (0.9% NaCl in deion-
zed water) using an intragastric cannula [20], while the
ontrol group received saline solution. Autoclaving (121 ◦C
or 15 min) was necessary for denature food lectins. Feed-
ng was restarted with ad libitum water and autoclaved
how food (Rodent Laboratory Chow 5001. Saint Louis, MO,
SA). Feces form 4 rats per group were collected at 0, 24,
8, 72, 96 and 120 h, fecal protein was extracted in PBS,
ltered through a 0.22 mm membrane and agglutination
peciﬁc activity was determined by microscopic counting
22]. Other 4 rats per group were sacriﬁced at 24 h in order
o recover blood for CBC (CellDyn® 1600) and a commer-
ial kit for differential blood cells staining was used for
ell counting from blood smear (Hycel, Mexico; cat. num-
er 548). Erythrocytes, neutrophils, eosinophils, basophils,
ymphocytes, monocytes and platelets were counted using
 100× microscope objective. Results are expressed as
bsolute blood counts or percentage respect to control ani-
als.
.4. Tolerability study
Fifteen-week old male SD rats were randomly selected
n 2 groups (n = 12 per group). Treated rats were dosed
ith 50 mg/kg TBLF dissolved in saline solution and con-
rol group was administered with saline solution by using
n intragastric cannula. For CBC determination, 4 rats per
roup were daily administered for 30 days and sacriﬁced.
or the tolerability assessment, treated group was admin-
stered with the 50 mg/kg TBLF in saline solution every
hird day for 6 weeks and control group administered with
aline solution. This administration schedule was deﬁned
rom the digestion resistance data and it will be used
n further studies, i.e. against colon cancer. Food intake
as determined twice a week and body weight weekly.
fter the 6-week administration schedule, rats were sac-
iﬁced by decapitation. Blood was collected in vacutainer
ubes without anticoagulant and serum was recovered by
entrifugation at 5000 × g for 5 min  and stored at −80 ◦C
ntil use for clinical chemistry parameters determina-
ion as described below. Liver, kidney, stomach, pancreas,
mall intestine, colon, thymus and spleen were dissected,
eighted and ﬁxed in 10% buffered formalin. A veterinary
athologist conducted the histopathological analyses for
iver, kidney, small intestine and colon using Hematoxylin-
osin staining and analyzed by microscopy (Olympus,
odel BX51, Evolution MP).
Commercial kits (Diagnostic Chemicals Limited,anada) were used for determination of liver function
sing aspartate aminotransferase (AST) (Catalog No.
19-10), alanine aminotransferase (ALT) (Catalog No.
18-10) and total bilirubin (Catalog No. 243-17) kits. Urea(3)  glycoprotein PASS, (4) western blot using anti-phytohemagglutinin
from Phaseolus vulgaris.
(Catalog No. 283-17) and -amylase (Catalog No. 341-10)
were measured as renal and pancreas function markers,
respectively. Serum creatinine (Catalog No. 221-30),
total protein (Catalog No. 200-55), glucose (SL ELITech,
Clinical Systems, France. Catalog No. B01-4509-01), and
albumin (SL ELITech, Clinical Systems, France. Catalog
No. ALBU-0600) were determined as nutritional status
markers.
2.5. Statistical analysis
Differences between TBLF treated rats against control
rats were calculated by the t-student test (p ≤ 0.05) using
the SPSS 17 software.
3. Results and discussion
3.1. TBLF proﬁle
The molecular weight exclusion chromatography proto-
col shows a reproducible proﬁle for TBLF obtainment. The
method allows observing the two  main lectins (Fig. 1), sim-
ilar than the observed proﬁle previously obtained [19]. The
presence of lectins was  conﬁrmed by PASS and western
blot. The speciﬁc agglutination activity for the TBLF was
5566 AU/protein mg.
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Fig. 2. Agglutination activity from rat feces administrated with TBLF. Rats
were administrated with a single dose of TBLF (50 mg/kg) and feces were
recollected every 24 h for 5 days. Agglutination activity was determined
using A+ human erythrocytes. Asterisks show statistical signiﬁcant differ-
ence (t test p ≤ 0.05).
3.2. Lectins from TBLF resist digestion up to 72 h
Some lectins exhibit high resistance to digestion by pro-
teolytic enzymes in mammals, allowing them to effectively
bind to intestinal epithelial cells. Lectins can also resist bac-
terial degradation and can remain in their biological and
immunological intact forms [5–7]. It has been reported that
this kind of proteins can be recovered with their intact bio-
logical activity after passing through the digestive tract of
mice over a period of 24 h as Pisum sativum and Kintoki
bean lectins [27–29]. In order to establish the resistance to
gastric digestion of TBLF, agglutination activity was mon-
itored through 120 h in feces after a 50 mg/kg TBLF single
dose (Fig. 2). Agglutination activity in TBLF-treated rats was
8 and 4 times higher than in control rats after 24 and 48 h,
respectively. However, instead of diminishing, it increased
15 times after 72 h and then gradually diminished until
basal levels at 120 h. This result suggests that no retained
lectin was excreted within the ﬁrst 48 h and retained lectin
releases after 72 h maintaining its biological activity.
3.3. TBLF exhibits an allergic-like response after 24 h
CBC is shown in Table 1 where only granulocytes count
showed difference (p = 0.001) with an increase of 3.86 times
in TBLF-treated animals respect to control rats. The pro-
portion of granulocytes and lymphocytes was different
respect to control animals, mainly due to an increment of
Table 1
CBC after 24 h of a single-dose TBLF oral administration.
Blood parameter
White blood cells (103/L) 
Lymphocytes (103/L) 
Granulocytes (103/L) 
Red blood cells (106/L) 
Platelets (103/L) 
Hemoglobin (g/dL) 
Hematocrit (%) 
Mean  corpuscular volume (fL) 
Mean  corpuscular hemoglobin (pg) 
Mean  corpuscular hemoglobin concentration (g/dL) 
* Statistically signiﬁcant difference (t test, p = 0.001).y Reports 2 (2015) 63–69
granulocytes (Fig. 3A). Blood smears were used to differ-
ential counting of cells (Fig. 3B). Lymphocytes decreased
20% while neutrophils and eosinophils increased 2.4 and
20 times, respectively. Basophils, monocytes, erythrocytes,
and platelets did not show signiﬁcant changes (data not
shown). This result suggests an allergic-like response,
mainly indicated by the eosinophils increase.
3.4. Six weeks TBLF administration provoked partial
reduction of food intake and decrease in body weight gain
Fifty mg/kg TBLF dose was  administrated via intra-
gastric cannula every third day for 6 weeks. Signiﬁcant
decreased in food consumption was  observed from the
ﬁrst week of administration until the fourth week respect
to control group (p ≤ 0.05). However, on the ﬁfth week,
food consumption was the same than the control group
(Fig. 4A), maybe as the result of compensatory mecha-
nisms where the treated animals overcame the negative
effects of the lectins administration. Rats body weight also
showed signiﬁcant changes (p ≤ 0.05) between the two
groups (Fig. 4B). Treated animals presented a transient
decrease of body weight in the ﬁrst weeks (5.25% respect
to the start of dosing) however; at the end of the study, a
recovery of weight was observed resulting in a reduction
in body weight gain of 10% respect to the control group.
It is known that lectins can provoke nonspeciﬁc interfer-
ence with nutrient absorption, causing changes in animal
nutrition status. Our results show that TBLF administration
causes antinutritional effects at the beginning of the exper-
iment with a ﬁnal recovery, which resulted in a reduction
in body weight gain.
3.5. Six weeks TBLF administration did not cause organs
or blood markers alterations
The effect of TBLF on organs and blood markers is shown
in Table 2. No signiﬁcant differences were observed in
spleen, heart, liver, kidney, stomach, thymus, pancreas,
small intestine and colon weight. Small intestine and colon
length were also determined and no signiﬁcant differ-
ences were found with respect to the control group. No
histopathological alterations were observed in colon, small
intestine, liver and kidney (Fig. 5). A strong association
between changes in the morphology and structure of the
intestine and the ingestion of lectins have been observed,
Control TBLF
5.16 ± 1.35 6.78 ± 1.56
4.70 ± 1.27 5.00 ± 1.44
0.46 ± 0.21 1.78 ± 0.53*
6.73 ± 0.20 6.55 ± 1.59
874.40 ± 84.97 737.75 ± 216.71
12.50 ± 0.37 12.24 ± 2.88
42.20 ± 1.06 40.76 ± 9.52
62.80 ± 2.77 62.40 ± 1.14
18.60 ± 0.99 18.74 ± 0.33
29.62 ± 0.77 30.00 ± 0.48
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Fig. 3. White blood cells counting after 24 h of a single dose of TBLF. CBC was  determined and blood cells were counted from blood smears by differential
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ounting. Results are expressed as percentage respect to control anima
 ≤ 0.05).
uch changes may  result from the decrease in intestinal
ermeability as shown with Con A, wheat agglutinin and
avy bean lectin. The intestinal growth is maybe the result
f compensatory process in order to maintain nutrient
ptake, since some lectins directly stimulate intestinal cells
ausing hyperplasia and hypertrophy [9]. However, TBLF
t the tested dose din not provoked macroscopic effects or
istological changes on the intestinal tract.
Different blood markers were determined in order to
tudy hepatotoxicity (AST and ALT), renal injury (urea, cre-
tinine), pancreatic damage (-amylase), and nutritional
ig. 4. Food intake and body weight changes after TBLF oral administration. Rat
eeks  after an adaptation period (7 days). Dosing was done to complete 6 week
A)  Net food intake, (B) Net body weight changes. Asterisks show statistical signiﬁtomated counting. (B) White cells count was determined by microscopic
ogarithmic scale. Asterisks show statistical signiﬁcant difference (t test
status (albumin, total protein, creatinine and glucose). No
differences between groups were found, suggesting that
the oral TBLF administration exhibit no toxicity at the end
of the treatment (Table 3). Urea levels were found out
of range, according to reference values for SD rats [30]
but the high values applied to both, control and treated
animals. To ﬁnd out if blood parameters could change
during the treatment, in a separated experiment total pro-
tein, albumin, creatinine and ALT were measured every 2
weeks and CBC was  determined after 4 weeks. No signif-
icant differences between groups were found, suggesting
s were orally administrated with TBLF (50 mg/kg) every third day for 6
s, from day 1 to day 42 (arrows indicate the start and end of treatment).
cant difference (t test p ≤ 0.05).
68 R. Ferriz-Martínez et al. / Toxicology Reports 2 (2015) 63–69
e orally
d observFig. 5. Histopatological analysis after TBLF oral administration. Rats wer
small  intestine, liver and kidney were collected after sacriﬁce, stained an
no adverse effects after long-term treatment (data not
shown).
Other studies have observed that intragastric admin-
istration of saline extract of P. acutifolius to rats caused
intestinal cells microvilli destruction, as well as break-
ing of endoplasmic reticulum outline [31]. These authors
attributed the toxicity and poor nutritional value of P.
acutifolius to high concentrations of phytohemagglutinin,
however, it is known that Tepary bean protease inhibitor
is also present in crude protein extracts [17]. TBLF does
not contain the protease inhibitor form Tepary bean as a
result of the chromatographic procedure [19]. Therefore,
Table 2
Organs weight or length after TBLF subchronic oral administration.
Organs Control TBLF
Colon weight (g) 2.94 ± 0.40 2.68 ± 0.40
Colon length (cm) 19.38 ± 1.14 19.60 ± 0.81
SI  weight (g) 8.06 ± 0.23 8.28 ± 0.52
SI  length (cm) 125.96 ± 2.40 122.02 ± 5.08
Spleen (g) 0.84 ± 0.03 0.83 ± 0.05
Heart (g) 1.65 ± 0.06 1.52 ± 0.06
Liver (g) 11.98 ± 0.42 10.57 ± 0.37
Kidneys (g) 3.31 ± 0.12 3.18 ± 0.15
Stomach (g) 2.21 ± 0.08 2.14 ± 0.07
Thymus (g) 0.45 ± 0.04 0.48 ± 0.05
Pancreas (g) 1.46 ± 0.27 1.73 ± 0.12
No statistically signiﬁcant difference was founded (t test, p ≥ 0.05).
Table 3
Blood markers after TBLF subchronic oral administration.
Blood markers Control TBLF
Glucose (mg/dL, RV: 50–160) 93.5 ± 7.10 96.9 ± 6.69
TP  (mg/dL, RV: 5.9–7.9) 8.3 ± 0.30 8.4 ± 0.44
ALB  (mg/dL, RV: 3.8–4.8) 3.2 ± 0.02 2.9 ± 0.13
AST (U/L, RV: 39–262) 186.7 ± 21.50 160.1 ± 10.90
ALT (U/L, RV: 35–80) 65.5 ± 3.10 66.8 ± 4.93
Urea (mmol/L, RV: 9.28–22.13) 29.5 ± 4.03 30.8 ± 5.07
Serum creatine (mg/dL, RV: 0.5–1.5) 0.9 ± 0.02 0.9 ± 0.02
-Amylase (U/L, RV: NA) 2.0 ± 0.04 1.9 ± 0.07
No statistically signiﬁcant difference was founded (t test, p ≥ 0.05).
TP: Total protein, ALB: Albumin, AST: Aspartate aminotransferase, ALT:
Alanine aminotransferase, RV: Reference values (16), NA: Data not avail-
able. administrated with TBLF (50 mg/kg) every third day for 6 weeks. Colon,
ed (10×).
the results obtained in the present work could be attributed
to the lectins contained in TBLF.
4. Conclusions
Here we report that after subchronic oral administra-
tion, TBLF provoked antinutritional effects in rats resulting
in a transient decrease of food intake and body weight in
he ﬁrst weeks. The ﬁnal result was observed as a reduc-
tion in body weight gain respect to the control group. The
digestion assay suggests that lectins from Tepary bean can
remain intact into the digestive tract up to 72 h. CBC at
24 h post-administration showed an allergic-like response
that disappeared after 4 weeks of treatment. Blood markers
suggest no toxic effects and no alterations in the evalu-
ated organs. Taking together, our results showed that TBLF
provoke a reduction in body weight gain with no other
remaining effects, suggesting compensatory mechanisms
and good tolerability. More studies are needed to deter-
mine effects on nutrient availability and intestinal integrity
after TBLF administration, especially in long-term assays
and in different development stages.
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